COVID‐19 and Older Adults: What We Know

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a novel virus that causes COVID‐19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hyp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Geriatrics Society (JAGS) 2020-05, Vol.68 (5), p.926-929
Hauptverfasser: Shahid, Zainab, Kalayanamitra, Ricci, McClafferty, Brendan, Kepko, Douglas, Ramgobin, Devyani, Patel, Ravi, Aggarwal, Chander Shekher, Vunnam, Ramarao, Sahu, Nitasa, Bhatt, Dhirisha, Jones, Kirk, Golamari, Reshma, Jain, Rohit
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 929
container_issue 5
container_start_page 926
container_title Journal of the American Geriatrics Society (JAGS)
container_volume 68
creator Shahid, Zainab
Kalayanamitra, Ricci
McClafferty, Brendan
Kepko, Douglas
Ramgobin, Devyani
Patel, Ravi
Aggarwal, Chander Shekher
Vunnam, Ramarao
Sahu, Nitasa
Bhatt, Dhirisha
Jones, Kirk
Golamari, Reshma
Jain, Rohit
description Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a novel virus that causes COVID‐19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease (CKD). A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and CKD are placed on angiotensin‐converting enzyme (ACE) inhibitors and angiotensin II receptor blockers. Studies have shown that these medications upregulate the ACE‐2 receptor, the very receptor that the SARS‐CoV‐2 virus uses to enter host cells. Although it has been hypothesized that this may cause a further increased risk of infection, more studies on the role of these medications in COVID‐19 infections are necessary. In this review, we discuss the transmission, symptomatology, and mortality of COVID‐19 as they relate to older adults, and possible treatments that are currently under investigation. J Am Geriatr Soc 68:926–929, 2020
doi_str_mv 10.1111/jgs.16472
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_wiley_primary_10_1111_jgs_16472_JGS16472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2387255747</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5372-e71352b528a85251ab488773acfc50df580a18552806a59af454a56c69f7051e3</originalsourceid><addsrcrecordid>eNp1kU9PwjAYhxujEUQPfgGzxIscBm23dy0eTAgqoiQc_MOxKVsHI2PDdpNw8yP4Gf0kVodETeylh_fJk_f3_hA6JrhF7GvPp6ZFAp_RHVQn4FEXfAK7qI4xpi4PiF9DB8bMMSYUc76Pah6lAIBZHTV7o6fB5fvrG-k4MoucURop7XSjMi3MuTOeycIZK-cuy1eHaC-WqVFHm7-BHq-vHno37nDUH_S6QzcEj1FXMeIBnQDlkgMFIic-54x5MoxDwFEMHEvCwc5xIKEjYx98CUEYdGKGgSivgS4q77KcLFQUqqzQMhVLnSykXotcJuL3JEtmYpq_CEYDG4tYwdlGoPPnUplCLBITqjSVmcpLI6jHmY3PfGbR0z_oPC91ZuMJ6mOPMRZQsFSzokKdG6NVvF2GYPFZgLAFiK8CLHvyc_st-X1xC7QrYJWkav2_Sdz27yvlBzXKjCc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2403777625</pqid></control><display><type>article</type><title>COVID‐19 and Older Adults: What We Know</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Shahid, Zainab ; Kalayanamitra, Ricci ; McClafferty, Brendan ; Kepko, Douglas ; Ramgobin, Devyani ; Patel, Ravi ; Aggarwal, Chander Shekher ; Vunnam, Ramarao ; Sahu, Nitasa ; Bhatt, Dhirisha ; Jones, Kirk ; Golamari, Reshma ; Jain, Rohit</creator><creatorcontrib>Shahid, Zainab ; Kalayanamitra, Ricci ; McClafferty, Brendan ; Kepko, Douglas ; Ramgobin, Devyani ; Patel, Ravi ; Aggarwal, Chander Shekher ; Vunnam, Ramarao ; Sahu, Nitasa ; Bhatt, Dhirisha ; Jones, Kirk ; Golamari, Reshma ; Jain, Rohit</creatorcontrib><description>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a novel virus that causes COVID‐19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease (CKD). A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and CKD are placed on angiotensin‐converting enzyme (ACE) inhibitors and angiotensin II receptor blockers. Studies have shown that these medications upregulate the ACE‐2 receptor, the very receptor that the SARS‐CoV‐2 virus uses to enter host cells. Although it has been hypothesized that this may cause a further increased risk of infection, more studies on the role of these medications in COVID‐19 infections are necessary. In this review, we discuss the transmission, symptomatology, and mortality of COVID‐19 as they relate to older adults, and possible treatments that are currently under investigation. J Am Geriatr Soc 68:926–929, 2020</description><identifier>ISSN: 0002-8614</identifier><identifier>EISSN: 1532-5415</identifier><identifier>DOI: 10.1111/jgs.16472</identifier><identifier>PMID: 32255507</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>Aged ; Angiotensin II ; Angiotensin-converting enzyme inhibitors ; Betacoronavirus ; Cardiovascular diseases ; coronavirus ; Coronavirus Infections - diagnosis ; Coronavirus Infections - mortality ; Coronavirus Infections - physiopathology ; Coronavirus Infections - therapy ; Coronaviruses ; COVID-19 ; COVID‐19‐Related Content ; Diabetes ; Diabetes mellitus ; Disease ; Humans ; Hypertension ; Infections ; Kidney diseases ; Mortality ; Non-Randomized Controlled Trials as Topic ; older adults ; Older people ; Pandemics ; Pneumonia, Viral - diagnosis ; Pneumonia, Viral - mortality ; Pneumonia, Viral - physiopathology ; Pneumonia, Viral - therapy ; Respiratory diseases ; Review ; Risk Factors ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2</subject><ispartof>Journal of the American Geriatrics Society (JAGS), 2020-05, Vol.68 (5), p.926-929</ispartof><rights>2020 The American Geriatrics Society</rights><rights>2020 The American Geriatrics Society.</rights><rights>2020 American Geriatrics Society and Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5372-e71352b528a85251ab488773acfc50df580a18552806a59af454a56c69f7051e3</citedby><cites>FETCH-LOGICAL-c5372-e71352b528a85251ab488773acfc50df580a18552806a59af454a56c69f7051e3</cites><orcidid>0000-0002-0716-8338 ; 0000-0002-4767-9095</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjgs.16472$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjgs.16472$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32255507$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shahid, Zainab</creatorcontrib><creatorcontrib>Kalayanamitra, Ricci</creatorcontrib><creatorcontrib>McClafferty, Brendan</creatorcontrib><creatorcontrib>Kepko, Douglas</creatorcontrib><creatorcontrib>Ramgobin, Devyani</creatorcontrib><creatorcontrib>Patel, Ravi</creatorcontrib><creatorcontrib>Aggarwal, Chander Shekher</creatorcontrib><creatorcontrib>Vunnam, Ramarao</creatorcontrib><creatorcontrib>Sahu, Nitasa</creatorcontrib><creatorcontrib>Bhatt, Dhirisha</creatorcontrib><creatorcontrib>Jones, Kirk</creatorcontrib><creatorcontrib>Golamari, Reshma</creatorcontrib><creatorcontrib>Jain, Rohit</creatorcontrib><title>COVID‐19 and Older Adults: What We Know</title><title>Journal of the American Geriatrics Society (JAGS)</title><addtitle>J Am Geriatr Soc</addtitle><description>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a novel virus that causes COVID‐19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease (CKD). A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and CKD are placed on angiotensin‐converting enzyme (ACE) inhibitors and angiotensin II receptor blockers. Studies have shown that these medications upregulate the ACE‐2 receptor, the very receptor that the SARS‐CoV‐2 virus uses to enter host cells. Although it has been hypothesized that this may cause a further increased risk of infection, more studies on the role of these medications in COVID‐19 infections are necessary. In this review, we discuss the transmission, symptomatology, and mortality of COVID‐19 as they relate to older adults, and possible treatments that are currently under investigation. J Am Geriatr Soc 68:926–929, 2020</description><subject>Aged</subject><subject>Angiotensin II</subject><subject>Angiotensin-converting enzyme inhibitors</subject><subject>Betacoronavirus</subject><subject>Cardiovascular diseases</subject><subject>coronavirus</subject><subject>Coronavirus Infections - diagnosis</subject><subject>Coronavirus Infections - mortality</subject><subject>Coronavirus Infections - physiopathology</subject><subject>Coronavirus Infections - therapy</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID‐19‐Related Content</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Disease</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Infections</subject><subject>Kidney diseases</subject><subject>Mortality</subject><subject>Non-Randomized Controlled Trials as Topic</subject><subject>older adults</subject><subject>Older people</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - diagnosis</subject><subject>Pneumonia, Viral - mortality</subject><subject>Pneumonia, Viral - physiopathology</subject><subject>Pneumonia, Viral - therapy</subject><subject>Respiratory diseases</subject><subject>Review</subject><subject>Risk Factors</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><issn>0002-8614</issn><issn>1532-5415</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU9PwjAYhxujEUQPfgGzxIscBm23dy0eTAgqoiQc_MOxKVsHI2PDdpNw8yP4Gf0kVodETeylh_fJk_f3_hA6JrhF7GvPp6ZFAp_RHVQn4FEXfAK7qI4xpi4PiF9DB8bMMSYUc76Pah6lAIBZHTV7o6fB5fvrG-k4MoucURop7XSjMi3MuTOeycIZK-cuy1eHaC-WqVFHm7-BHq-vHno37nDUH_S6QzcEj1FXMeIBnQDlkgMFIic-54x5MoxDwFEMHEvCwc5xIKEjYx98CUEYdGKGgSivgS4q77KcLFQUqqzQMhVLnSykXotcJuL3JEtmYpq_CEYDG4tYwdlGoPPnUplCLBITqjSVmcpLI6jHmY3PfGbR0z_oPC91ZuMJ6mOPMRZQsFSzokKdG6NVvF2GYPFZgLAFiK8CLHvyc_st-X1xC7QrYJWkav2_Sdz27yvlBzXKjCc</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Shahid, Zainab</creator><creator>Kalayanamitra, Ricci</creator><creator>McClafferty, Brendan</creator><creator>Kepko, Douglas</creator><creator>Ramgobin, Devyani</creator><creator>Patel, Ravi</creator><creator>Aggarwal, Chander Shekher</creator><creator>Vunnam, Ramarao</creator><creator>Sahu, Nitasa</creator><creator>Bhatt, Dhirisha</creator><creator>Jones, Kirk</creator><creator>Golamari, Reshma</creator><creator>Jain, Rohit</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0716-8338</orcidid><orcidid>https://orcid.org/0000-0002-4767-9095</orcidid></search><sort><creationdate>202005</creationdate><title>COVID‐19 and Older Adults: What We Know</title><author>Shahid, Zainab ; Kalayanamitra, Ricci ; McClafferty, Brendan ; Kepko, Douglas ; Ramgobin, Devyani ; Patel, Ravi ; Aggarwal, Chander Shekher ; Vunnam, Ramarao ; Sahu, Nitasa ; Bhatt, Dhirisha ; Jones, Kirk ; Golamari, Reshma ; Jain, Rohit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5372-e71352b528a85251ab488773acfc50df580a18552806a59af454a56c69f7051e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Angiotensin II</topic><topic>Angiotensin-converting enzyme inhibitors</topic><topic>Betacoronavirus</topic><topic>Cardiovascular diseases</topic><topic>coronavirus</topic><topic>Coronavirus Infections - diagnosis</topic><topic>Coronavirus Infections - mortality</topic><topic>Coronavirus Infections - physiopathology</topic><topic>Coronavirus Infections - therapy</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID‐19‐Related Content</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Disease</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Infections</topic><topic>Kidney diseases</topic><topic>Mortality</topic><topic>Non-Randomized Controlled Trials as Topic</topic><topic>older adults</topic><topic>Older people</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - diagnosis</topic><topic>Pneumonia, Viral - mortality</topic><topic>Pneumonia, Viral - physiopathology</topic><topic>Pneumonia, Viral - therapy</topic><topic>Respiratory diseases</topic><topic>Review</topic><topic>Risk Factors</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shahid, Zainab</creatorcontrib><creatorcontrib>Kalayanamitra, Ricci</creatorcontrib><creatorcontrib>McClafferty, Brendan</creatorcontrib><creatorcontrib>Kepko, Douglas</creatorcontrib><creatorcontrib>Ramgobin, Devyani</creatorcontrib><creatorcontrib>Patel, Ravi</creatorcontrib><creatorcontrib>Aggarwal, Chander Shekher</creatorcontrib><creatorcontrib>Vunnam, Ramarao</creatorcontrib><creatorcontrib>Sahu, Nitasa</creatorcontrib><creatorcontrib>Bhatt, Dhirisha</creatorcontrib><creatorcontrib>Jones, Kirk</creatorcontrib><creatorcontrib>Golamari, Reshma</creatorcontrib><creatorcontrib>Jain, Rohit</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the American Geriatrics Society (JAGS)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shahid, Zainab</au><au>Kalayanamitra, Ricci</au><au>McClafferty, Brendan</au><au>Kepko, Douglas</au><au>Ramgobin, Devyani</au><au>Patel, Ravi</au><au>Aggarwal, Chander Shekher</au><au>Vunnam, Ramarao</au><au>Sahu, Nitasa</au><au>Bhatt, Dhirisha</au><au>Jones, Kirk</au><au>Golamari, Reshma</au><au>Jain, Rohit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID‐19 and Older Adults: What We Know</atitle><jtitle>Journal of the American Geriatrics Society (JAGS)</jtitle><addtitle>J Am Geriatr Soc</addtitle><date>2020-05</date><risdate>2020</risdate><volume>68</volume><issue>5</issue><spage>926</spage><epage>929</epage><pages>926-929</pages><issn>0002-8614</issn><eissn>1532-5415</eissn><abstract>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a novel virus that causes COVID‐19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease (CKD). A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and CKD are placed on angiotensin‐converting enzyme (ACE) inhibitors and angiotensin II receptor blockers. Studies have shown that these medications upregulate the ACE‐2 receptor, the very receptor that the SARS‐CoV‐2 virus uses to enter host cells. Although it has been hypothesized that this may cause a further increased risk of infection, more studies on the role of these medications in COVID‐19 infections are necessary. In this review, we discuss the transmission, symptomatology, and mortality of COVID‐19 as they relate to older adults, and possible treatments that are currently under investigation. J Am Geriatr Soc 68:926–929, 2020</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>32255507</pmid><doi>10.1111/jgs.16472</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-0716-8338</orcidid><orcidid>https://orcid.org/0000-0002-4767-9095</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0002-8614
ispartof Journal of the American Geriatrics Society (JAGS), 2020-05, Vol.68 (5), p.926-929
issn 0002-8614
1532-5415
language eng
recordid cdi_wiley_primary_10_1111_jgs_16472_JGS16472
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Aged
Angiotensin II
Angiotensin-converting enzyme inhibitors
Betacoronavirus
Cardiovascular diseases
coronavirus
Coronavirus Infections - diagnosis
Coronavirus Infections - mortality
Coronavirus Infections - physiopathology
Coronavirus Infections - therapy
Coronaviruses
COVID-19
COVID‐19‐Related Content
Diabetes
Diabetes mellitus
Disease
Humans
Hypertension
Infections
Kidney diseases
Mortality
Non-Randomized Controlled Trials as Topic
older adults
Older people
Pandemics
Pneumonia, Viral - diagnosis
Pneumonia, Viral - mortality
Pneumonia, Viral - physiopathology
Pneumonia, Viral - therapy
Respiratory diseases
Review
Risk Factors
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
title COVID‐19 and Older Adults: What We Know
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T12%3A36%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID%E2%80%9019%20and%20Older%20Adults:%20What%20We%20Know&rft.jtitle=Journal%20of%20the%20American%20Geriatrics%20Society%20(JAGS)&rft.au=Shahid,%20Zainab&rft.date=2020-05&rft.volume=68&rft.issue=5&rft.spage=926&rft.epage=929&rft.pages=926-929&rft.issn=0002-8614&rft.eissn=1532-5415&rft_id=info:doi/10.1111/jgs.16472&rft_dat=%3Cproquest_pubme%3E2387255747%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2403777625&rft_id=info:pmid/32255507&rfr_iscdi=true